Long‐term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (<scp>FILO</scp>)-Reference-Cited by-同舟云学术

Long‐term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO)

Published:2024-03-19 Issue:6 Volume:204 Page:2233-2236
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Laribi Kamel¹^ORCID,Poulain Stéphanie²,Willems Lise³,Merabet Fatiha⁴,Herbaux Charles⁵^ORCID,Roos‐Weil Damien⁶^ORCID,Laribi de Materre Inès⁷,Roussel Xavier⁸,Nudel Morgane⁹,Tricot Sabine¹⁰,Dupuis Jehan¹¹,Le Calloch Ronan¹²^ORCID,Bareau Benoit¹³,Leblond Véronique⁶

Affiliation:

1. Haematology Department Le Mans Hospital Le Mans France

2. Cellular Haematology, Biology and Pathology Center Lille Regional and University Hospital and INSERM UMR 1172, IRCL Lille France

3. Haematology Clinic Cochin Hospital, APHP Paris France

4. Haematology and Oncology Clinic André Mignot Hospital, Versailles Hospital Versailles France

5. Haematology Clinic Montpellier University Hospital Montpellier France

6. Haematology Department APHP, Sorbonne University, University Hospital La Pitié Salpêtrière‐Charles Foix Paris France

7. Paris Centre University Paris France

8. Haematology Department University of Franche‐Comté, INSERM UMR 1098, Besançon University Hospital Besançon France

9. Haematology Department Lille Regional and University Hospital Lille France

10. Haematology Clinic Valenciennes Hospital Valenciennes France

11. Lymphoid Malignancies Unit APHP, Henri Mondor‐Albert Chennevier Hospital Créteil France

12. Internal Medicine, Infectiology and Blood Diseases Cornouaille Hospital Center Quimper France

13. Haematology and Internal Medicine Clinic Sévigné Vivalto Santé Private Hospital Cesson‐Sévigné France

Abstract

SummaryThe bendamustine–rituximab (BR) schedule is an efficient first‐line therapy in Waldenström macroglobulinaemia (WM). A previous analysis of 69 patients who received this treatment confirmed a high response rate and good progression‐free (PFS) and overall survival (OS). With a median follow‐up of 76.1 months (95% confidence interval [CI] 69.9–80.6), 5‐year outcome is still excellent at 66.63% (95% CI 56.09–79.17) for PFS and 80.01% (95% CI 70.82–90.41) for OS. The rate of secondary cancers is 17.66% (IQR 7.99–27.64) at 66 months. Relapsed patients who received ibrutinib as second‐line clearly benefited from this schedule. This confirms current recommendations suggesting BR long‐term efficacy as first‐line option in WM.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.19409

Reference10 articles.

1. How I treat Waldenström macroglobulinemia

2. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

3. Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus

4. Bendamustine plus rituximab in newly‐diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO)

5. New developments in the diagnosis and characterization of Waldenström’s macroglobulinemia